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TREATMENT OF A COMMON OCULAR
COMPLAINT
To the Editor: Or W. Rakusin' makes reference to the com-
parative efficacy of two ophthalmic solutions containing
different concentrations of zinc sulphate.
Having experimented quite extensively with eyedrops in
animals, I should like to say that unless Or Rakusin can
assure us that the solutions he compared were in all respects
identical, except for the differences in the zinc concentrations,
his conclusions, as expressed, are not acceptable.
Differences in excipients such as buffers, thickeners, pre-
servatives, stabilizers, etc., can all alter the efficacy. Most
marketed eyedrops containing zinc sulphate are formulated
with one or more other active ingredients such as naphazoline,
tetrahydrozoline, phenylephrine, antazoline, etc. If other active
agents were also present in the solutions used, were they the
same, and were they present in identical concentrations?
Many 'clinical trials' compare the efficacy of different mar-
keted products that are intended for the treatment of the
same condition/so If this is what Or Rakusin did, then his
comments are of value, but one must know which of the
available options he chose to follow before his conclusions
can be taken at all seriously.
J. L. Straughan
Department of Pharmacology
University of Stellenbosch
Parowvallei, CP
1. Rakusin, W. (1979): S. Afr. med. J., SS, 3.
Dr W. Rakusin comments: I agree with Or Straughan's
comments that buffers and preservatives, etc., alter the efficacy
of the drops. The two drops used in the trial were Ocufort,
which contains zinc sulphate 0,1 %, phenylephrine hydro-
chloride 0,12% and tetrahydrozoline 0,4%, herbs and aromatic
water in an isotonic sterile eyedrop solution, and Oculosan,
which contains zinc sulphate 0,02%, naphazoline 0,005'%, herbs
and aromatic water in an isotonic sterile eyedrop solution.
The vehicle in each drop was obviously not identical.
However, the aims of the trial were (I) to ascertain the
effectivity of Ocufort as an astringent and decongestant com-
pared with a known astringent, Oculosan; (ii) to determine the
safety of Ocufort and its lack of side-effects; and (iil) to
determine \?atient tolerance of Ocufort.
HEARTFELT THANKS
To the Editor: I wish, through the courtesy of your Journal,
to record my appreciation of and gratitude to my colleagues
in this town.
During 1972 I developed a postinfective myelopathy, with
resulting paraplegia, and could not attend to my duties for
a long time. My colleagues came to my rescue by attending
to my practice, and even lent financial aid.
Since I have returned to active practice, they have helped
me by doing visits on my behalf, as well as performing
operations for me.
I am also most grateful to several specialist neurologists,
neurosurgeons and urologists who have attended me on various
occasions, in Cape Town, Johannesburg and Port Elizabeth.
Money could never express the gratitude I owe to all these
people.
J. L. D. Paisley
62 Caledon Street
Uitenhage, CP
The only abnormality found on routine investigation was
a serum uric acid level of 9,1 mg/lOO ml. It was decided to
defer treatment of his hypertension until his uric acid level,
through medication, returned to normal. Within 6 weeks the
uric acid level had decreased to 5,7 mg/l00 ml, and the blood
pressure was 120/80 mmHg, and has remained so.
The patient's son, aged 17 years, presented shortly after-
wards with pain in his right knee; he had suffered pain and
swelling of the joints since childhood. Periodic investigations
(which had never included estimation of the serum uric acid
level) were negative, and he was said to be 'rheumatoid'. An
estimation of serum uric acid revealed a level of 9,1 mg/100
ml. His two siblings, aged 15 and 12 years, were then
investigated, and were found to have uric acid levels of
10,4 mg/lOO ml and 7,9 mg/lOO ml respectively.
Hyperuricaemia is tranSmitted as a dominant autosomal
gene with different degrees of penetration in the two sexes,'
and 90% of patients are male.
I now do the following as a routine:
In the case of every new hypertensive patient with a raised
serum uric acid level, I lower the uric acid level to normal
before treating the hypertension.
In every confirmed case of hyperuricaemia, I screen the
whole family, as is done in cases of hypercholesterolaemia
diabetes, etc. '
For every child with a musculoskeletal complaint, I include
a uric acid determination in the differential diagnosis.
There are certain matters which are still not clear con-
cerning children, viz. (i) at what stage should the serum uric
acid level be considered to be sufficiently high for treatment
to be instituted? (ii) at what age should a child be treated?
(iii) should the child be treated if he has no symptoms? and
(iv) having regard for the sequelae, should a child be sub-
jected to treatment for life?
I. Shapiro
PO Box 131
Carletonville, Tvl
I. Vaughan, V. C. and McKay, R. J., eds (1975): Nelson's Textbook of
Pediatries, lOth ed., p. 448. Philadelphia: W. B. Saunders.
SMOKING AND INSURANCE POLICIES
To the Editor: With regard to the correspondence'" about
smoking and life insurance, I should like to ask whether
the tobacco companies invest large sums of money with life
insurance companies?
G. P. Charlewood
919 Medical Centre
Jeppe Street
Johannesburg
1. Muller, H. (1978). S. Afr. med. J., 54, 594.
2. Haifer, M. (1978)' Ibid., 54, 1043.
ERRATA
In the book review entitled 'Achalasia of the cardia', by
W. Silber, which appeared on page 229 of the SAMJ of 10
February 1979, there was an error in the fifth sentence of the
first paragraph, which should have read as follows:
'The term cardiospasm should be excluded. It should not
be used synonymously with achalasia which is neither a
disease of the cardia nor a spasm.' '
OBSERVATIONS ON HYPERURICAEMIA * * *
To the Editor: A White man aged 44 years presented with
a blood pressure of 160/110 mmHg. He was free of symptoms
and otherwise healthy. His wife, a qualified nursing sister,
had been taking his blood pressure for some time previously,
and had found it to be elevated.
In the article 'A possible role of prolactin in preventing
heartburn during pregnancy', which appeared on page 127
of the SAMJ of 27 January 1979, the degrees of one of the
co-authors, Or E. J. Robertson, should have been M.B. B.Ch.,
M.D,
